Complete Treatment Comparison: Stock Status & Clinical Facts
Wegovy vs Ozempic vs Mounjaro: UK Stock Availability Analysis
The landscape of GLP-1 treatments has created significant confusion around availability, with many patients unable to access their prescribed medications consistently. Currently, Wegovy faces the most complex supply situation, having experienced global shortages throughout 2023-2024. However, EverydayMeds maintains direct supply agreements with Novo Nordisk, ensuring all five Wegovy doses (0.25mg through 2.4mg) remain available for immediate dispatch. Ozempic, whilst sharing the same active ingredient as Wegovy, is licensed exclusively for type 2 diabetes management and cannot legally be prescribed for weight management in the UK.
Mounjaro presents a different availability picture, with more consistent stock levels due to its newer market entry and dual-mechanism approach. However, the 21-day room temperature storage limitation can create logistical challenges for patients who travel frequently. At EverydayMeds, we stock Mounjaro alongside Wegovy, allowing prescribers to recommend the most suitable option based on individual patient needs rather than availability constraints. Our GPhC-registered pharmacy (#9012878) processes orders within standard 3 working days, with express 24-hour prescriber reviews available for urgent requirements.
Pricing Breakdown: Wegovy vs Mounjaro Cost Analysis
Understanding the true cost comparison between Wegovy vs Ozempic vs Mounjaro requires examining both individual doses and progression pathways. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. New customers apply code FIRST40 at checkout to reach these final prices, whilst returning customers use code DOSE25. Our Intro Duo bundle (0.25mg & 0.5mg) provides the first 8 weeks of treatment for £169.99, ensuring seamless dose progression without separate orders.
Mounjaro follows a different dosing structure with 2.5mg, 5mg, 7.5mg, 10mg, and 15mg strengths, each requiring separate prescriptions and cost considerations. The key advantage of our Wegovy bundles lies in Reliable Supply continuity rather than cost savings. Our Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, eliminating concerns about dose availability during critical treatment phases. This pricing transparency allows patients to plan their weight management investment accurately, unlike competitors who hide final costs until checkout.
Clinical Evidence: STEP Trials vs SURMOUNT Studies
When comparing Wegovy vs Ozempic vs Mounjaro through clinical evidence, it's crucial to understand that direct head-to-head trials don't exist, making percentage comparisons inappropriate. Wegovy's efficacy comes from the comprehensive STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The recent SELECT trial also showed a 20% reduction in major cardiovascular events, expanding Wegovy's clinical profile beyond weight management.
Mounjaro's evidence base stems from the SURMOUNT trials, showing its dual GIP/GLP-1 receptor mechanism in weight management contexts. However, comparing trial outcomes directly between these studies would be misleading due to different patient populations, trial designs, and primary endpoints. Both treatments require prescription-only medicine status and comprehensive clinical assessment to determine suitability for individual patients.
Mechanism Differences: GLP-1 vs Dual Agonist Approaches
Understanding how Wegovy works compared to Mounjaro reveals fundamental differences in their pharmacological approaches. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which is released when food enters the small intestine. This mechanism promotes feelings of fullness, reduces appetite, and may help control food cravings by acting on appetite centres in the brain. The GLP-1 pathway also slows gastric emptying, extending the period between meals when patients feel satisfied. Ozempic contains identical semaglutide but is formulated and licensed specifically for type 2 diabetes management, not weight management.
EverydayMeds Ordering Process: Assessment to Delivery
Our streamlined process for Wegovy vs Ozempic vs Mounjaro begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Once submitted, our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring each patient receives appropriate treatment recommendations based on MHRA licensing and NICE guidelines. Upon approval, medications are dispatched via next-day delivery using cold-chain transportation to maintain the required 2-8°C temperature throughout transit. All packaging includes temperature monitoring to ensure product integrity upon arrival. Patients receive tracking information and handling instructions to ensure proper storage immediately upon delivery.
Storage and Practical Considerations: Travel-Friendly Options
Storage requirements create practical differences when choosing between Wegovy vs Ozempic vs Mounjaro for active lifestyles. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigerated storage, making it ideal for extended travel or business trips. In contrast, Mounjaro allows only 21 days at room temperature, requiring more careful planning for longer journeys. Both treatments use pre-filled FlexTouch pen systems for easy injection, with clear dose escalation schedules that must be followed precisely. The 4-week dose escalation protocol for Wegovy (0.25mg→0.5mg→1mg→1.7mg→2.4mg) allows gradual tolerance building, whilst Mounjaro follows its own progression pathway. Neither medication should be frozen, and both require disposal through pharmacy return schemes rather than household waste.
Supply Chain Reliability: Why Stock Matters for Treatment Success
The importance of reliable stock availability when comparing Wegovy vs Ozempic vs Mounjaro cannot be overstated, as treatment interruptions can compromise weight management progress. Global supply constraints have affected Wegovy availability worldwide, with some patients experiencing month-long gaps between prescriptions. EverydayMeds addresses this challenge through direct supply agreements with Novo Nordisk and proactive inventory management, maintaining at least 8 weeks of forward stock across all doses.
Our automated reorder system alerts patients 2 weeks before their current pen expires, allowing sufficient time for prescriber review and delivery scheduling. This reliability extends to our customer service team, who monitor individual patient progression through dose escalation phases and proactively communicate any potential supply considerations. Unlike single-dose orders from other providers, our bundle options ensure treatment continuity without multiple prescription requests or delivery coordination challenges.
Final Decision Support: Starting Your Weight Management Journey
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option aligns with your medical history and lifestyle requirements. New customers can begin with our Intro Duo bundle using code FIRST40, whilst returning customers apply DOSE25 at checkout for established pricing. Our clinical team remains available throughout your treatment journey to address questions about dose progression, side effects, or storage requirements. To begin your clinical assessment and access our current stock levels, visit https://everydaymeds.co.uk/collections/wegovy today. Remember that successful weight management requires commitment to alongside a reduced-calorie diet and increased physical activity, regardless of which prescription-only medicine you choose.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
